Aurinia Q1 revenue $77.7M (+24% YoY), EPS $0.25 (+56%); reiterates FY guidance

Aurinia Pharmaceuticals Inc.

2026-Q1 EPS reported $0.25 vs consensus $0.20 ▲ beat (+23.8%)

Net product sales of LUPKYNIS were $73.6M, up 23% YoY.
Net income of $34.4M, up 48% YoY; diluted EPS $0.25 vs $0.16.
Cash from operations surged to $32.6M from $1.3M a year ago.
Repurchased 2.5M shares for $36.2M during Q1.
Reaffirms 2026 total revenue guidance of $315M–$325M and net product sales of $305M–$315M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Aurinia Pharmaceuticals Inc. updated its the three months ended March 31, 2026 guidance (reaffirmed).

Period: the three months ended March 31, 2026
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Aurinia Pharmaceuticals Inc. (Aurinia or the Company) issued a press release announcing its financial results for the quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

Aurinia Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001600620-26-000048

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.